Who’s at high risk after RCC surgery? Real-world clues from French registry
Official title: Identification and Description of Patients With High-risk Non Metastatic RCC (UroCCR 127)
Run by University Hospital, Bordeaux · NCT07753343 · Data updated 2026-11-12
This study looks at real-world data from French RCC patients who had local or high-risk locally advanced disease to see how they do after surgery and how doctors decide on adjuvant treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 6109 (estimated) |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Drugs / interventions | pembrolizumab |
| Locations | 1 site (Bordeaux) |
| Status | Recruiting |
| Started | April 17, 2026 |
| Main results expected | April 17, 2028 |
| Study ends | April 17, 2028 |
| Registry record updated | August 7, 2026 |
| Trial ID | NCT07753343 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with local RCC or high-risk locally advanced RCC who are in the UroCCR database and consent to participate, without metastatic disease at inclusion.
✕Probably not a fit
Patients with metastatic disease at inclusion or those not linked between UroCCR and SNDS data sources may not benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study uses the UroCCR-Chain registry in France to describe the natural history, management, and outcomes of non-metastatic renal cell carcinoma. It aggregates real-world data from multiple cohorts to identify patterns in recurrence, treatment choices, and associated costs. The goal is to inform postoperative risk assessment and help clinicians weigh adjuvant pembrolizumab decisions in high-risk patients. The analysis focuses on patients diagnosed between 2014 and 2023 who are linked across UroCCR and SNDS data sources, excluding metastatic cases and hereditary RCC. Findings may support more cost-effective, personalized post-surgical care for localized and locally advanced RCC.
Why it matters
Potential benefit: If successful, the study could improve risk stratification after RCC surgery and help guide which patients may benefit from adjuvant therapies.
How similar studies have gone: Real-world data analyses in oncology have informed post-surgical management in RCC, though specific French registry-based insights for high-risk non-metastatic RCC are less established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients diagnosed with local RCC or high-risk locally advanced RCC, * Included in UroCCR register between 1st january 2014 and 31st december 2023, * Consenting to participate in UroCCR and UroCCR-Chain registers. Exclusion Criteria: * Patients with metastatic disease at inclusion, * Patients not linked between UroCCR and SNDS datasources, * Patients with hereditary RCC.
Where it's running
-
CHU Bordeaux
Bordeaux, France Recruiting
Study contacts
- Principal investigator: Jean-Christophe BERNHARD, Pr — University Hospital, Bordeaux
- Study coordinator: Jean-Christophe BERNHARD, Pr
- Email: jean-christophe.bernhard@chu-bordeaux.fr
- Phone: 0033540451179
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Plasma DNA Methylation to Classify Kidney Masses Before Surgery
This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.
-
Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home
This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.
-
Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer
We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.
-
First-in-human test of HH160 in people with advanced solid tumors
HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.
-
Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer
This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.
-
Cold ischemia during robot-assisted partial nephrectomy
This trial will test whether using ice around the kidney during robot-assisted partial nephrectomy helps the operated kidney recover function faster in adults with kidney cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.